<DOC>
	<DOCNO>NCT00305903</DOCNO>
	<brief_summary>This prospective , 26-week , open-label , single-arm multi-center pilot study . Eligible patient receive open-label treatment rivastigmine capsule plus memantine tablet add therapy . This study design evaluate safety tolerability add therapy memantine rivastigmine capsule patient probable AD ( MMSE 10-20 )</brief_summary>
	<brief_title>Safety Tolerability Rivastigmine With Add-on Memantine Patients With Probable Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Have diagnosis probable Alzheimer 's disease ; Have MMSE score 10 20 ; Must able swallow capsule/tablet ; Must caregiver able attend study visit ; Have advance , severe , progressive , unstable disease type may interfere efficacy safety assessment put patient special risk ; Have current diagnosis active , uncontrolled seizure disorder ; Have history within past year current diagnosis cerebrovascular disease Have current diagnosis severe unstable cardiovascular disease ; Had myocardial infarction ( MI ) within last six month ; Have specific respiratory , digestive , renal , endocrine disorder ; Have previous treatment rivastigmine memantine ; Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Dementia ,</keyword>
	<keyword>Alzheimer 's ,</keyword>
	<keyword>Rivastigmine ,</keyword>
	<keyword>Memantine</keyword>
</DOC>